Clinical Trials Archive - Page 7 of 16

recruiting PHASE3 Oncology NCT06952504

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

Researchers are looking for new ways to treat people with proficient mismatch repair (pMMR) endometrial cancer (EC) that is advanced or recurrent. * EC is a type of cancer that…

Sponsor: Merck Sharp & Dohme LLC

View Trial ClinicalTrials.gov ↗

recruiting PHASE3 Oncology NCT06170788

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival (OS). The primary hypothesis is that the combination…

Sponsor: Merck Sharp & Dohme LLC

View Trial ClinicalTrials.gov ↗

recruiting PHASE3 Oncology NCT06966700

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or…

Sponsor: Merck Sharp & Dohme LLC

View Trial ClinicalTrials.gov ↗

recruiting PHASE3 Oncology NCT06623422

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want…

Sponsor: Merck Sharp & Dohme LLC

View Trial ClinicalTrials.gov ↗

recruiting PHASE4 Respiratory / COPD / Asthma NCT06444113

Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis

This study will evaluate whether ofatumumab is excreted at quantifiable levels and at which concentrations in breast milk of lactating women with RMS). The study will include lactating mothers who…

Sponsor: Novartis Pharmaceuticals

View Trial ClinicalTrials.gov ↗

recruiting PHASE2 Respiratory / COPD / Asthma NCT04302870

Motor Neurone Disease – Systematic Multi-Arm Adaptive Randomised Trial

MND-SMART is investigating whether selected drugs can slow down the progression of motor neuron disease (MND) and improve survival. The study is 'multi-arm' meaning more than one treatment will be…

Sponsor: University of Edinburgh

View Trial ClinicalTrials.gov ↗

recruiting NA Neurology NCT07452562

Hesperidin RCT in MS

This study is a randomised, double-blind, placebo-controlled trial investigating the effects of Hesperidin supplementation on cognitive function, fatigue, and stress. Participants will be randomly assigned to receive either 500mg of…

Sponsor: Swansea University

View Trial ClinicalTrials.gov ↗

recruiting Neurology NCT05123443

Longitudinal Assessment of Iron Rims in MS Lesions

In multiple sclerosis (MS), the presence of white matter lesions surrounded by a rim of iron is suggested to signify a more severe disease course. Iron rim lesions can be…

Sponsor: Nottingham University Hospitals NHS Trust

View Trial ClinicalTrials.gov ↗

recruiting PHASE3 Cardiology / Cardiovascular NCT07225504

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

The purpose of this study is to provide efficacy and safety data for remibrutinib in patients with secondary progressive multiple sclerosis (SPMS)

Sponsor: Novartis Pharmaceuticals

View Trial ClinicalTrials.gov ↗

recruiting PHASE1 Oncology NCT07139743

Obe-cel in Refractory Progressive Forms of Multiple Sclerosis

The main purpose of this study is to evaluate if obe-cel is safe or causes any side effects in adults with refractory progressive MS. The study also plans to assess…

Sponsor: Autolus Limited

View Trial ClinicalTrials.gov ↗

Clinical Trials

Join 10,000+ UK Clinicians